Spyre Therapeutics Inc (NASDAQ: SYRE) kicked off on Tuesday, down -4.52% from the previous trading day, before settling in for the closing price of $19.02. Over the past 52 weeks, SYRE has traded in a range of $17.24-$43.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -49.91%. While this was happening, its average annual earnings per share was recorded -12.04%. With a float of $51.14 million, this company’s outstanding shares have now reached $60.26 million.
The extent of productivity of a business whose workforce counts for 65 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Spyre Therapeutics Inc (SYRE) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Spyre Therapeutics Inc is 15.13%, while institutional ownership is 93.76%. The most recent insider transaction that took place on Nov 06 ’24, was worth 246,313. In this transaction Director of this company sold 6,700 shares at a rate of $36.76, taking the stock ownership to the 27,360 shares. Before that another transaction happened on Oct 25 ’24, when Company’s Director sold 300 for $36.43, making the entire transaction worth $10,929. This insider now owns 34,060 shares in total.
Spyre Therapeutics Inc (SYRE) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -12.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.20% during the next five years compared to 44.65% growth over the previous five years of trading.
Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators
Take a look at Spyre Therapeutics Inc’s (SYRE) current performance indicators. Last quarter, stock had a quick ratio of 11.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.16, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -3.66 in one year’s time.
Technical Analysis of Spyre Therapeutics Inc (SYRE)
The latest stats from [Spyre Therapeutics Inc, SYRE] show that its last 5-days average volume of 0.67 million was superior to 0.62 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 50.28%. Additionally, its Average True Range was 1.42.
During the past 100 days, Spyre Therapeutics Inc’s (SYRE) raw stochastic average was set at 4.00%, which indicates a significant decrease from 24.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.13% in the past 14 days, which was lower than the 62.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.72, while its 200-day Moving Average is $26.50. Now, the first resistance to watch is $19.26. This is followed by the second major resistance level at $20.35. The third major resistance level sits at $21.21. If the price goes on to break the first support level at $17.31, it is likely to go to the next support level at $16.45. Assuming the price breaks the second support level, the third support level stands at $15.36.
Spyre Therapeutics Inc (NASDAQ: SYRE) Key Stats
The company with the Market Capitalisation of 1.09 billion has total of 60,257K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -208,020 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -56,300 K.
